ASCO GI 2021 | DEEPER: FOLFOXIRI + cetuximab or bevacizumab for 1L mCRC

Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, disucsses the safety analysis results of the DEEPER trial, a randomized Phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).